Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 11/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 5/20 | 1.00 |
| ▸ | LGALS9 | O00182 | 4/20 | 1.00 |
| ▸ | LGALS8 | O00214 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiodigalactoside SCHEMBL13385542 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Thiodigalactoside SCHEMBL5520730 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Thiodigalactoside SCHEMBL13404791 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Thiodigalactoside SCHEMBL7642586 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Thiodigalactoside SCHEMBL15150644 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Thiodigalactoside SCHEMBL4758536 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Thiodigalactoside SCHEMBL28458993 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Thiodigalactoside SCHEMBL13770726 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| Thiodigalactoside SCHEMBL5520725 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL13770716 | 0.88 | LGALS3 (0.78) | LGALS3LGALS1LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128913-A1 | INHIBITION OF ENDOSOMAL ESCAPE DETECTION TO AMELIORATE THE INFLAMMATORY SIDE-EFFECTS OF LIPID NANOPARTICLES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-06-19 | — | — | WO | claimed |
| CN-114272382-A | Application and pharmaceutical composition of Galectin-3 inhibitor | 上海中医药大学 | 2022-04-05 | — | — | CN | claimed |
| US-9770503-B2 | Immunomodulating compositions and uses therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2017-09-26 | — | — | US | claimed |
| EP-2591786-B1 | Immunomodulating compositions and uses therefor | CANCURE LTD (AU) | 2017-04-12 | — | — | EP | claimed |
| US-20170095496-A1 | GALACTOSIDE INHIBITORS FOR NEW USES | GALECTO BIOTECH AB (DK) | 2017-04-06 | — | — | US | claimed |
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | claimed |
| US-20150265701-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | CANCURE LIMITED ACN 164 438 359 (AU) | 2015-09-24 | — | — | US | claimed |
| EP-2919802-A1 | METHODS, COMPOSITIONS AND KITS FOR TREATING, MODULATING, OR PREVENTING OCULAR ANGIOGENESIS OR FIBROSIS IN A SUBJECT USING A GALECTIN PROTEIN INHIBITOR | Tufts University (US) | 2015-09-23 | — | — | EP | claimed |
| US-9050352-B2 | Immunomodulating compositions and uses therefor | CANCURE LIMITED ACN 164 438 359 (AU) | 2015-06-09 | — | — | US | claimed |
| WO-2014078655-A1 | METHODS, COMPOSITIONS AND KITS FOR TREATING, MODULATING, OR PREVENTING OCULAR ANGIOGENESIS OR FIBROSIS IN A SUBJECT USING A GALECTIN PROTEIN INHIBITOR | TUFTS UNIVERSITY (US) | 2014-05-22 | — | — | WO | claimed |
| JP-2007508328-A | — | — | 2007-04-05 | — | — | JP | claimed |
| WO-2007021721-A2 | GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS | GLYCOMIMETICS, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20070037775-A1 | drugs having a high receptivity for hemagglutinins, used for diagnosis and therapy of bacterial infections | GLYCOMIMETICS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| EP-1682159-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | Ralph, John Stephen (AU) | 2006-07-26 | — | — | EP | claimed |
| WO-2005037293-A1 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR | UNIV MONASH (AU) | 2005-04-28 | — | — | WO | claimed |
| WO-1998008535-A2 | METHOD OF CAUSING SELECTIVE IMMUNOSUPPRESSION USING HL-60-RELATED LECTINS | INCYTE PHARMACEUTICALS, INC. (US) | 1998-03-05 | — | — | WO | claimed |
| US-5710257-A | Method of causing selective immunosuppression using HL-60-related lectins | SEILHAMER JEFFREY J (US) | 1998-01-20 | — | — | US | claimed |
| US-5693760-A | SPECIFIC AMINO ACID SEQUENCE CONSISTING OF POSITION 2-135 INCLUDES A GLYCOSYLATION SITE WITHIN POSITION 96-98, BINDS BETA-GLALACTOSIDE CONTAINING MOIETIES INDEPENDENT OF ABSENCE OF PRESENCE OF CALCIUM IONS, STIMULATES HEMAGGLUTINATION | INCYTE PHARMACEUTICALS, INC. (US) | 1997-12-02 | — | — | US | claimed |
| US-5587460-A | CONTROLLER OF CELL DIFFERENTIATION; IMMUNOLOGY | INCYTE PHARMACEUTICAL CORPORATION (US) | 1996-12-24 | — | — | US | claimed |
| WO-1994011497-A1 | METHOD OF CAUSING SELECTIVE IMMUNOSUPPRESSION USING HL-60-RELATED LECTINS | INCYTE PHARMACEUTICALS, INC. (US) | 1994-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | LGALS1, LGALS2, LGALS3BP | LGALS3 4/4885LGALS1 1/4885LGALS9 7/4885 |
| US-20170095496-A1 | GALACTOSIDE INHIBITORS FOR NEW USES | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885LGALS9 9/4885 |
| US-20070037775-A1 | drugs having a high receptivity for hemagglutinins, used for diagnosis and therapy of bacterial infections | CFTR, CD44, HDGF | LGALS3 287/4885LGALS1 100/4885LGALS9 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.